Singlon 5mg 28 chewable tablets — Made in Hungary — Free Delivery

Treatment of bronchial asthma

Prevention of exercise-induced bronchospasm in patients over 2 years of age.

Relief of symptoms of seasonal and perennial allergic rhinitis.

Hypersensitivity to montelukast or to any of the excipients of the preparation.

Age up to 2 years.

Interaction with other medicinal products and other types of interactions.

active substance: montelukast

1 chewable tablet of 4 mg contains 4 mg of montelukast (in the form of sodium montelukast - 4.16 mg)

1 chewable tablet 5 mg 5 mg montelukast (in the form of sodium montelukast - 5.2 mg)

excipients: mannitol (E 421), microcrystalline cellulose, hydroxypropyl cellulose, croscarmellose sodium, cherry flavor (maltodextrin, modified starch, maltol), aspartame (E 951), iron oxide yellow (E172), magnesium stearate.

The preparation should be used in children under adult supervision.

Patients with bronchial asthma and allergic rhinitis (seasonal and year-round) should take 1 chewable tablet 4 mg once a day. To relieve the symptoms of allergic rhinitis, the time of admission should be selected individually.

For the treatment of bronchial asthma, the dose for children aged 2 to 5 years is

Children 6-14 years old: 1 chewable tablet (5 mg) once a day (in the evening, 1:00 before or 2:00 after eating). There is no need to adjust the dosage for this age group.

General recommendations. The therapeutic effect of the preparation Singlon on the control parameters of bronchial asthma occurs within 1 day. Patients should be advised to continue taking Singlon, even if asthma control is achieved, as well as during periods of exacerbation of asthma.

There is no need for dose adjustment in patients with impaired renal function or with mild to moderate hepatic impairment. There are no data on patients with severe liver dysfunction. The same doses are used for boys and girls.

Alternative treatment instead of low-dose inhaled corticosteroids for persistent mild bronchial asthma. Montelukast is not recommended as monotherapy in patients with moderate persistent asthma. The use of montelukast as an alternative to low-dose inhaled corticosteroids in children with persistent mild asthma should be considered only for patients who have not recently had severe asthma attacks, require oral corticosteroids, and cannot use inhaled corticosteroids. Mild persistent bronchial asthma is defined as the onset of asthma symptoms more often than 1 time per week, but less than 1 time per day, the occurrence of nighttime symptoms more often 2 times a month, but less often than 1 time per week, and normal lung function in the periods between episodes of bronchial asthma. If sufficient control of asthma is not achieved, in the future (usually within 1 month) the need for additional or other anti-inflammatory therapy should be determined, based on the consistent treatment of bronchial asthma symptoms. The condition of patients should be periodically assessed for the control of bronchial asthma.

Prevention of bronchial asthma in patients aged 2 to 5 years, in which the main component of bronchial asthma is exercise-induced bronchospasm. Singlon is recommended for patients aged 2 to 5 years for the prevention of exercise-induced bronchospasm, which can be the main manifestation of persistent bronchial asthma, requires the use of inhaled corticosteroids. Patients should be assessed after 2-4 weeks of montelukast treatment. If a sufficient response is not achieved, additional or other therapy should be considered.

Treatment with Singlon, depending on other means of treating bronchial asthma. If Singlon is used as an adjunct to inhaled corticosteroids, Singlon should not abruptly replace inhaled corticosteroids.

The preparation Singlon, chewable tablets, 4 mg should be used in children aged 2 to 5 years.

The preparation Singlon, chewable tablets, 5 mg should be used in children aged 6 to 14 years.

Safety and efficacy in children under 2 years of age have not been established.